0FIW Stock Overview
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Embla Medical hf. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.29.60 |
| 52 Week High | kr.33.90 |
| 52 Week Low | kr.27.45 |
| Beta | 0.59 |
| 1 Month Change | -12.03% |
| 3 Month Change | 1.20% |
| 1 Year Change | -6.33% |
| 3 Year Change | -37.95% |
| 5 Year Change | -14.57% |
| Change since IPO | -83.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0FIW | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 2.3% |
| 1Y | -6.3% | -9.3% | 0.6% |
Price Volatility
| 0FIW volatility | |
|---|---|
| 0FIW Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 3,999 | Sveinn Solvason | www.ossur.com |
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics, Bracing & Supports, and Patient Care. The Prosthetics segment offers mechanical products, such as lower limb prosthetics and finger prostheses; and bionic products microprocessor-controlled feet, knees, hands, liners, fingers, and other components integrated.
Embla Medical hf. Fundamentals Summary
| 0FIW fundamental statistics | |
|---|---|
| Market cap | kr.13.15b |
| Earnings (TTM) | kr.395.93m |
| Revenue (TTM) | kr.5.59b |
31.5x
P/E Ratio2.2x
P/S RatioIs 0FIW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0FIW income statement (TTM) | |
|---|---|
| Revenue | US$804.32m |
| Cost of Revenue | US$310.36m |
| Gross Profit | US$493.96m |
| Other Expenses | US$437.03m |
| Earnings | US$56.93m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 23, 2024
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 61.41% |
| Net Profit Margin | 7.08% |
| Debt/Equity Ratio | 57.4% |
How did 0FIW perform over the long term?
See historical performance and comparison